20 (AIDX) Equity Ratio (2024 - 2026)
20 posted quarterly Equity Ratio of 0.44 for Q1 2026, up 9566.94% on a QoQ basis from 0.0 in Q4 2025.
20 (AIDX) has 3 years of Equity Ratio data on file, last reported at 0.44 in Q1 2026.
- For the quarter ending Q1 2026, Equity Ratio changed N/A year-over-year to 0.44; the trailing twelve-month figure through Mar 2026 stood at 0.44 (changed N/A YoY), and the FY2025 full-year result was 0.0, down 101.11% from the prior year.
- Equity Ratio for Q1 2026 stood at 0.44, up from 0.0 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.44 in Q1 2026 and bottomed at 0.0 in Q4 2025.
- The 3-year median for Equity Ratio is 0.42 (2024), against an average of 0.29.
- Peak annual rise in Equity Ratio reached 101.11% in 2025, while the deepest fall reached 101.11% in 2025.
- A 3-year view of Equity Ratio shows it stood at 0.42 in 2024, then tumbled by 101.11% to 0.0 in 2025, then jumped by 9566.94% to 0.44 in 2026.
- The last three Equity Ratio figures came in at 0.44 (Q1 2026), 0.0 (Q4 2025), and 0.42 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 0.47 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 0.50 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 0.54 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 0.59 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 0.78 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 0.45 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 0.29 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 0.67 |
| 10 | 20 | - | - | 62,884.00 | 0.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.44 |
| Dec 31, 2025 | 0.00 |
| Dec 31, 2024 | 0.42 |